

The cell surface receptor Slamf6 modulates innate immune responses during *Citrobacter rodentium*-induced colitis

Boaz van Driel¹, Guoxing Wang¹, Gongxian Liao¹, Peter J. Halibozek¹, Marton Keszei¹, Michael S. O’Keeffe¹, Atul K. Bhan², Ninghai Wang¹ and Cox Terhorst¹

¹Department of Medicine, Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston 02115, MA, USA

²Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, MA, USA

Correspondence to: C. Terhorst, 3 Blackfan Circle, Room CLS 938, Boston 02115, MA, USA; E-mail: cterhors@bidmc.harvard.edu

Received 5 April 2015, accepted 28 April 2015

Abstract

The homophilic cell surface receptors CD150 (Slamf1) and CD352 (Slamf6) are known to modulate adaptive immune responses. Although the T_H17 response was enhanced in *Slamf6*^{-/-} C57BL/6 mice upon oral infection with *Citrobacter rodentium*, the pathologic consequences are indistinguishable from an infection of wild-type C57BL/6 mice. Using a reporter-based binding assay, we show that Slamf6 can engage structures on the outer cell membrane of several Gram⁻ bacteria. Therefore, we examined whether Slamf6, like Slamf1, is also involved in innate responses to bacteria and regulates peripheral inflammation by assessing the outcome of *C. rodentium* infections in *Rag*^{-/-} mice. Surprisingly, the pathology and immune responses in the lamina propria of *C. rodentium*-infected *Slamf6*^{-/-} *Rag*^{-/-} mice were markedly reduced as compared with those of *Rag*^{-/-} mice. Infiltration of inflammatory phagocytes into the lamina propria was consistently lower in *Slamf6*^{-/-} *Rag*^{-/-} mice than in *Rag*^{-/-} animals. Concomitant with the reduced systemic translocation of the bacteria was an enhanced production of IL-22, suggesting that Slamf6 suppresses a mucosal protective program. Furthermore, administering a mAb (330) that inhibits bacterial interactions with Slamf6 to *Rag*^{-/-} mice ameliorated the infection compared with a control antibody. We conclude that Slamf6-mediated interactions of colonic innate immune cells with specific Gram⁻ bacteria reduce mucosal protection and enhance inflammation, contributing to lethal colitis that is caused by *C. rodentium* infections in *Rag*^{-/-} mice.

Keywords: *Citrobacter rodentium*, IL-22, innate, mucosal immunology, Slamf6

Introduction

Most hematopoietic cells express Slamf6, which is one of the nine signaling lymphocyte activating molecule (SLAM) family receptors. Slamf6 expression is highest in activated T cells and B cells, whereas expression in dendritic cells (DCs) and macrophages can be induced by inflammatory signals (1). Although Slamf6 signaling is extensively studied in adaptive immunity (2, 3), less is known about the function of Slamf6 in innate responses.

Several Slam family glycoproteins serve as receptors for certain pathogens (Table 1). For instance, human SLAMF1 is one of the receptors of Measles virus (4). Slamf2 is a receptor for the lectin present on pili of certain enterobacteriaceae (5). Recently, we found that Slamf1 can recognize the outer membrane porins OmpC and OmpF of *Escherichia coli* (6, 7). Furthermore, most of the Slamf receptors modulate mechanisms that protect against microbial challenges mediated

by signals that are induced by Slamf–Slamf homophilic ligation. For example in T cells and B cells, Slamf6 recruits SH-2-containing signal-transducing molecules to its intracellular intracellular tyrosine-based switch motives (ITSM) domains following homophilic ligation and receptor clustering, which is critically involved in germinal center reactions (3, 8). Table 1 summarizes the susceptibility of Slam receptor-deficient mice to various infectious agents that have been used in to study Slamf functions.

Here, we assess whether Slamf6, like Slamf1, might be a microbial sensor for bacteria, especially *E. coli* and *Citrobacter rodentium*, which both reside in the gastrointestinal tract. Furthermore, enterohemorrhagic *E. coli* and enteropathogenic *E. coli* are attaching bacteria that harbor a pathogenicity island that renders them capable of colonizing colonic epithelia and causing lesions resulting in a compromised mucosal barrier

Table 1. Slamf receptors and their adaptor SAP modulate susceptibility to microbes

	Expression	Receptor deficiency results in resistance to:	Receptor deficiency results in susceptibility to:	Slamf ligand	Microbial ligand
Slamf1, SLAM, CD150	T, B, mono, M ϕ , DC, plat, HSC	<i>Trypanosoma cruzi</i>	Gram ⁻ bacteria, <i>Leishmania major</i>	Slamf1	Measles virus <i>E. coli</i> (OmpC/F+) <i>S. typhimurium</i> <i>E. coli</i> (FimH+)
Slamf2, CD48	Pan-lymphocyte	<i>S. aureus</i>	FimH+ enterobacterae	Slamf4, CD2	—
Slamf3, Ly-9, CD229	T, B, iCD8, NKT, mono, M ϕ , HSC			Slamf3	—
Slamf4, 2B4, CD244	NK, NKT, T, B, $\gamma\delta$, CD8, DC, eo		LCMV, γ HV-68	Slamf2	—
Slamf5, CD84	Pan-lymphocyte, plat, mast, eo			Slamf5	—
Slamf6, NTB-A, Ly-108	NK, NKT, T, B, M ϕ , pDC, Neu	<i>Leishmania mexicana</i> , <i>C. rodentium</i>	<i>S. typhimurium</i>	Slamf6	<i>E. coli</i> , <i>C. rodentium</i>
Slamf7, CRACC, CS1, CD319	T, B, mono, DC, NK			Slamf7	—
Slamf8, BLAME	iCD8, mono, DC, M ϕ , Neu, endo, FRC			Slamf8	—
Slamf9, SF2001	T, B, mono, DC			???	—
SAP	NK, NKT, T, (B?)		Mouse: γ HV-68, LCMV, Influenza Human: EBV, some other viruses	Slamf1, 3, 4, 5, 6 Human only: Slamf7	N/A

γ HV-68, murine gamma-herpes virus 68; EBV, Epstein–Barr virus; FimH, bacterial lectin; LCMV, lymphocytic choriomeningitis virus; SAP, *Sh2d1a*, Slam-associated protein.

(9). They represent a major threat to global health, as they are responsible for a large number of cases of diarrhea that can be life threatening for infants and children. The closely related bacterium *C. rodentium* is a natural Gram⁻ murine pathogen, and oral infection with this bacterium results in an infectious colitis characterized by local T_H1 responses, neutrophil and macrophage recruitment and epithelial hyperplasia. T cells and B cells are necessary for sterilizing immunity to *C. rodentium* and mice that lack CD4⁺ T cells have systemic dissemination of bacteria (9–11).

To study the role of Slamf6 in innate immune responses, we employ *Slamf6*^{-/-} *Rag*^{-/-} and *Rag*^{-/-} mice, which solely rely on innate mechanisms to combat *C. rodentium* infections, because they lack T cells and B cells. The absence of T cells and B cells renders *Rag*^{-/-} mice unable to mount an effective immune response to *C. rodentium* and the infection results in severe and ultimately fatal colitis (12).

Roles for a range of innate cells have been implicated in the immunity against *C. rodentium*. Lamina propria CX₃CR1⁺ macrophages are key in the early detection of the bacterium and specific depletion of these macrophages leads to enhanced pathologic inflammation and more systemic translocation (13, 14). Upon activation, CX₃CR1⁺ macrophages produce IL-1 β , IL-12 and IL-23 as well as other inflammatory mediators (14, 15). The role of innate lymphocytes manifests predominantly through their production of IL-22, which contributes to mucosal protection by inducing the production of anti-microbial peptides and accelerating mucosal healing (16, 17).

Here, we report that, surprisingly, *Slamf6*-deficiency renders *Rag*^{-/-} mice resistant to *C. rodentium*-induced colitis, which suggests that Slamf6 negatively affects mucosal protection during colonic *C. rodentium* infection.

Methods

Mice

Slamf6^{-/-} *C57BL/6J* mice were described previously (18). These mice were interbred with *Rag1*^{-/-} mice that were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Age- and sex-matched wild-type (WT) and *Rag1*^{-/-} *C57BL/6J* mice were bred in-house and originally purchased from Jackson Laboratory. Mice were co-housed for at least 10 days prior to experimental use. All animals were maintained under specific pathogen-free conditions at the Center for Life Science animal facility of the Beth Israel Deaconess Medical Center (BIDMC) and were used at 8–13 weeks of age. The experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee at BIDMC.

Evaluating bacterial binding by the IL-2 luciferase assay

Chimeric constructs, consisting of extracellular Ig domains of the Slamf6 receptor fused with the signaling competent cytoplasmic domain of CD3 ζ , together with an IL-2 promoter-driven Firefly luciferase gene and Renilla luciferase under a mammalian promoter, are transfected into the Jurkat human T-cell line (6). Six hours after transfection, heat-inactivated bacteria are added as stimulation and incubated overnight. Cells are washed and lysed according to the manufacturer's protocol (Dual Luciferase Reporter Assay, Promega, Madison, WI, USA). Substrates for Firefly luciferase and subsequently Renilla luciferase are added to 10 μ l of the cell lysates and luminescence is measured using a standard Glomax luminometer (Promega). Values represent the ratio of Firefly and Renilla luminescence.

In vivo bacterial infection by oral gavage

Citrobacter rodentium (DBS100) (ATCC#51459) was cultured in LB-broth for 4 h and washed in PBS prior to inoculation via oral gavage. Bacteria (2×10^9) were resuspended in 200 μ l PBS, which was used for the inoculation of one mouse. The mice were monitored daily for morbidity and their weight was recorded every 3 or 4 days. Mice were sacrificed for analysis when their weight dropped below 80% of their starting weight or at the end of the experiment. Fresh stool pellets were collected in Eppendorf tubes for serial dilution in PBS and plating on MacConkey agar plates for quantification of colony forming units (CFU).

Treatment with an antibody directed against Slamf6

Rag^{-/-} mice were intra-peritoneally injected with 100 μ g anti-Slamf6 mAb (330) 1 day prior to infection and subsequently every seventh day after the first injection. Control mice were injected with 100 μ g mouse IgG2a in the same regimen.

Adoptive CD45RB^{hi} CD4⁺ T-cell transfer colitis

Adoptive transfer of CD45RB^{hi} CD4⁺ T cells into *Rag*^{-/-} *Slamf6*^{-/-} *Rag*^{-/-} recipients was described previously (19).

Histology

Fresh colon tissue was harvested and fixed in paraformaldehyde (10%). Hematoxylin & eosin (H&E) staining was performed on slices of the proximal, medial and distal part of the colon. Scoring was performed by an independent pathologist (A.K.B.) assessing: (i) mononuclear cell infiltration, (ii) epithelial integrity, (iii) hyperplasia and (iv) edema.

Flow cytometry

Macrophages and DCs were incubated with anti-CD16/32 antibody to block Fc receptors at 4°C for 20 min. All samples were stained with relevant antibodies on ice for 30 min. Dead cells were excluded using 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) (Roche, Indianapolis, IN, USA). The cells were acquired on a BD LSRII flow cytometer and the data analysis was performed using the FlowJo analysis package (Tree Star Inc., Ashland, OR, USA).

Cytokine analysis

Colons were harvested, washed in PBS with gentamycin (100 μ g ml⁻¹) and 100 mg tissue was cultured in 1 ml complete DMEM for 24 h. The amount of cytokines in the supernatant was analyzed using LEGENDplex reagents (Biolegend, San Diego, CA, USA) or CBA reagents (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions.

Taqman quantitative PCR

Fresh colon tissue was collected, washed in PBS and homogenized by sonication in TRIzol reagent (Life Technologies, Grand Island, NY, USA). The vendor's protocol was followed for RNA purification. FAM/MGB 16sRNA probes were used as control housekeeping genes. Commercially available FAM/MGB probes (Mm04203745_mH and Hs01011518_m1) were

used for *Il1fb* (IL-22) and *Il12b* [IL-12(p70)], respectively (Life Technologies). Analysis was performed using the 7500 FAST Real Time PCR.

Statistical analysis

The Prism 5.0 software (GraphPad, San Diego, CA, USA) was used for results analysis. Results are reported as mean \pm SEM. Most of the statistical comparisons were performed using the two-tailed Student's *t*-test. Values of *P* < 0.05 are considered to be statistically significant.

Results

Slamf6 engages in cognate interactions with several Gram⁻ bacteria

To investigate a possible role of Slamf6 in innate immune responses during bacterial infections, we first assessed potential interactions between Slamf6 and Gram⁻ *E. coli*, *Salmonella typhimurium* (*SseB*-), *C. rodentium* and the Gram⁺ bacterium *Staphylococcus aureus*. To this end, we used a cell-based reporter assay based on co-transfection of a DNA segment encoding a chimeric Slamf6/CD3 ζ together with an IL-2 promoter-driven luciferase gene into Jurkat cells (6). Cognate interactions between the Ig domain of Slamf6 and bacterial surface entities result in increased luciferase activity. Using this assay, specific interactions between Slamf6 and *E. coli* and *S. typhimurium* (*SseB*-), but not between Slamf6 or *S. aureus*, were detected (Fig. 1A). *Citrobacter rodentium* displayed binding to the ectodomain of Slamf6 (Fig. 1B), albeit to a far lesser extent. Mutated *E. coli* that lack OmpC, OmpF or both lost the ability to interact with the ectodomain of Slamf6, suggesting that these bacterial proteins contain both the Slamf6- and Slamf1-interacting structures (Fig. 1C) (6). Further analysis of the interaction between Slamf6 and *E. coli* revealed that anti-Slamf6 mAb blocked this interaction (Fig. 1D).

Structural studies that assessed the formation of human SLAMF6-SLAMF6 homodimers revealed 13 amino acid residues that are critical for this interaction (20). To evaluate whether these residues are also involved in bacterial interactions, we constructed three mutant Slamf6-CD3 ζ chimeras at positions that affect homodimer formation (Fig. 1E). These mutant Slamf6 molecules were capable of inducing a signal upon exposure to *E. coli*, suggesting that bacterial ligation does not involve amino acid residues that are essential in homodimer formation. Similar conclusions were made based upon the same type of analyses with mutants of human SLAMF6 and mouse Slamf1 (data not shown). Thus, the amino acids in the ectodomain of Slamf6 and Slamf1 that interact with structures in the outer cell wall of several Gram⁻ bacteria are different from the amino acid residues, which are requisite for formation of the homodimers.

Stronger T_h17 response in Slamf6^{-/-} mice during C. rodentium infection

To evaluate the effect of Slamf6 on immune responses to bacteria, we selected *C. rodentium*, which is a well-studied model organism that induces intestinal inflammation. First, *Slamf6*^{-/-} and WT C57BL/6 mice were orally infected with




Fig. 1. Slamf6 interacts with *E. coli* and *C. rodentium*. Relative luminescence measured in Jurkat cells that were transfected with a fusion construct of Slamf6 and CD3 ζ and a Renilla luciferase reporter. (A) The luciferase activity of Jurkat cells after o/n stimulation with serial dilutions of heat-inactivated *S. aureus*, *E. coli* (F18) or *S. typhimurium* and (B) *C. rodentium* (DS100). (C) The luciferase activity of Jurkat cells after o/n stimulation with *E. coli*, *E. coli* Δ OmpC, *E. coli* Δ OmpF or double-deficient *E. coli*. (D) The luciferase activity of Jurkat cells after o/n stimulation in the absence and presence of anti-Slamf6 mAb (330). (E) The luciferase activity of Jurkat cells in which single mutations were made, after o/n stimulation.

2×10^9 *C. rodentium* bacteria and analyzed for progression of colitis. Upon infection, both colonic macrophages and a set of CD11c⁻ cells express Slamf6 (Supplementary Figure 1A and B, available at *International Immunology Online*). Slamf6^{-/-} mice, like WT mice, showed a slight reduction in

their body weight on day 12 post-infection (Fig. 2A) with a fecal *C. rodentium* burden of $\sim 10^7$ CFU per mg feces. The fecal burden steadily declined after day 16 and both WT and Slamf6^{-/-} mice appeared to recover from the infection (Fig. 2B and C). Thus, Slamf6-deficiency has little impact on




Fig. 2. *Slamf6*^{-/-} mice are equally resistant to *C. rodentium*-induced colitis as WT mice. WT and *Slamf6*^{-/-} mice were infected by oral gavage of 2×10^9 *C. rodentium* bacteria. The animals were checked daily and sacrificed when their weight dropped below 80% of their starting weight. (A) The weight of individual mice was measured every 4 days and represented as a percentage of their weight on the day of infection. (B) Survival of infected WT and *Slamf6*^{-/-} mice. (C) *C. rodentium* counts of fecal pellets that were obtained directly from mice every 3 days. Serial dilutions were made in PBS and plated on MacConkey plates. Counted bacterial colonies are represented as CFU per g feces.

the pathogenesis of *C. rodentium*-induced colitis in the presence of an adaptive immune system.

As both T_h1 and T_h17 cells have been implicated in inflammation and mucosal protection during *C. rodentium* infections (21, 22), isolated T cells from infected WT and *Slamf6*^{-/-} mice were assessed for the production of IFN γ and IL-17A. Intracellular staining of these cells revealed that T_h17 cells are more prevalent in the lamina propria of *Slamf6*^{-/-} mice, compared with WT mice (Fig. 3A). However, an equal percentage of CD4⁺ IFN γ ⁺ T cells were found in the colonic lamina propria of WT and *Slamf6*^{-/-} mice (Fig. 3B and C), suggesting that T_h1 development is unaffected by Slamf6. To assess whether the enhanced percentage of T_h17 cells in the lamina propria of infected *Slamf6*^{-/-} mice is a T-cell intrinsic phenomenon, WT and *Slamf6*^{-/-} T cells were stimulated *in vitro*. The culture supernatant of *Slamf6*^{-/-} T cells contained significantly more IL-17A upon stimulation with α CD3 mAb compared with WT culture supernatant, while IFN γ production was similar (Fig. 3D and E). Experiments in which colitis-inducing CD45RB^{hi} CD4⁺ T cells were transferred to *Rag*^{-/-} mice also showed that *Slamf6*^{-/-} T cells are more prone to IL-17A production (Fig. 3F) (23), as the percentage of IL17A⁺ lymphocytes was significantly higher in *Rag*^{-/-} mice that had received *Slamf6*^{-/-} T cells, compared with WT T cells. Again, equal percentages of T_h1 cells were detected in the lamina propria of *Rag*^{-/-} mice 6 weeks after transfer of WT or *Slamf6*^{-/-} T cells (Fig. 3G and H). Taken together, the data suggest that Slamf6 inhibits the production of IL-17A by CD4⁺ T cells.

Slamf6^{-/-} *Rag*^{-/-} mice are resistant to *C. rodentium*

To focus on the role of Slamf6 in the surface of innate immune cells, *Slamf6*^{-/-} *Rag*^{-/-} and *Rag*^{-/-} mice were infected with *C. rodentium*. *Slamf6*^{-/-} *Rag*^{-/-} mice have a mucosal homeostasis that is similar to *Rag*^{-/-} mice before and after co-housing. However, after oral infection with 2×10^9 *C. rodentium*, *Slamf6*^{-/-} *Rag*^{-/-} mice are resistant to the typical lethal colitis that develops in *Rag*^{-/-} mice (Fig. 4) (10, 17, 22). The loss in weight that is caused by a progressing colitis in infected *Rag*^{-/-} mice, which starts 2 weeks after the oral gavage with *C. rodentium*, was not observed in *Slamf6*^{-/-} *Rag*^{-/-} mice (Fig. 4A). Ultimately, *Rag*^{-/-} mice are unable to manage the

infection, leading to diarrhea and fatal colitis (~60% at day 20), whereas all of the *Slamf6*^{-/-} *Rag*^{-/-} mice survived past day 24 (Fig. 4B).

Fecal cultures of infected mice reveal an expansion of the colonic bacterial burden over the first ~14 days after infection in both *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice. As expected, *Rag*^{-/-} mice were unable to control the *C. rodentium* burden after day 14, reaching $>10^{10}$ CFU per mg feces (11). In contrast, *Slamf6*^{-/-} *Rag*^{-/-} mice stabilize the bacterial burden at $\sim 10^7$ CFU per mg feces (Fig. 4C). *Slamf6*^{-/-} *Rag*^{-/-} mice were incapable of sterile clearance as late as day 40 post-infection (data not shown). Thus, *Slamf6*^{-/-} *Rag*^{-/-} mice can harbor *C. rodentium* without developing lethal colitis.

At day 18 post-infection when most *Rag*^{-/-} mice were moribund, *Slamf6*^{-/-} *Rag*^{-/-} mice showed a strongly reduced pathology of the colon (Fig. 4D and E). A loss in epithelial integrity as well as some inflammatory infiltration of mononuclear phagocytes was observed in *Slamf6*^{-/-} *Rag*^{-/-} mice. In contrast, *Rag*^{-/-} mice showed a strong reduction of epithelial integrity and more cellular infiltration, paired with submucosal edema (Fig. 4D). This indicates that mucosal barrier damage and inflammation as a consequence of *C. rodentium*-induced colitis is reduced in *Slamf6*^{-/-} *Rag*^{-/-} mice.

Citrobacter rodentium translocates to the spleen of both *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice

One of the major differences in the early response to *C. rodentium* between *Rag*^{-/-} and WT mice is the presence of mucosal CD4⁺ T cells. T_h1 cells localize at sites of bacterial lesions, produce IFN γ and aid in an early inflammatory response. However, T_h1 cells also contribute to immune pathology (10–12, 24). T_h17 cells are required to contain *C. rodentium* and to prevent aberrant intestinal pathology (25). Overall, the lack of T cells causes *Rag*^{-/-} mice to develop a systemic multi-bacterial infection past the second week after oral infection due to this loss of colon barrier integrity (12). Although pathologic features were significantly lower in *Slamf6*^{-/-} *Rag*^{-/-} mice (Fig. 4D and E), *C. rodentium* was detected in splenic homogenates of these mice when cultured on MacConkey agar plates. However, more *C. rodentium* CFU were cultured from *Rag*^{-/-} spleens (Fig. 4F). *Citrobacter rodentium* systemic




Fig. 3. Enhanced T_H17 response in *Slamf6*^{-/-} mice during *C. rodentium*-induced colitis. WT and *Slamf6*^{-/-} mice were infected by oral gavage of 2×10^9 *C. rodentium* bacteria. At day 10 post-infection, leukocytes were isolated from the colon lamina propria. The percentage of (A) IL-17A⁺ and (B) IFN γ ⁺ lymphocytes is represented as a percentage of total CD45⁺ CD4⁺ lymphocytes. (C) Representative dot plots of intracellular staining for IL-17A and IFN γ obtained from WT and *Slamf6*^{-/-} mice. Isolated CD4⁺ splenocytes were cultured o/n in the presence of plate-bound anti-CD3 antibody. The amount of (D) IL-17A and (E) IFN γ cytokines in the supernatant of these cultures is represented. WT and *Slamf6*^{-/-} CD45RB^{hi} CD4⁺ splenocytes were transferred into *Rag*^{-/-} mice. The percentage of (F) IL-17A⁺ and (G) IFN γ ⁺ lymphocytes is represented as a percentage of total CD45⁺ CD4⁺ lymphocytes. (H) Representative dot plot of intracellular staining for IL-17A and IFN γ obtained from *Rag*^{-/-} mice in which WT T cells were transferred.

translocation manifested in mice with both genetic backgrounds, albeit to a lesser extent in *Slamf6*^{-/-} *Rag*^{-/-} mice. This indicates that the mucosal barrier is less compromised in *Slamf6*^{-/-} *Rag*^{-/-} mice.

Reduced inflammation in *Slamf6*^{-/-} *Rag*^{-/-} mice during *C. rodentium* infection

Having established that the absence of *Slamf6* in T-cell- and B-cell-deficient mice improves the health of infected animals,




Fig. 4. *Slamf6*^{-/-} *Rag*^{-/-} mice are resistant to *C. rodentium*-induced colitis, while *Rag*^{-/-} mice are not. *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice were infected by oral gavage of 2×10^9 *C. rodentium* bacteria. The animals were checked daily and sacrificed when their weight dropped below 80% of their starting weight. (A) The weight of individual mice was measured every 3 days and represented as a percentage of their weight on the day of infection. (B) Survival of infected *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice. (C) *C. rodentium* counts of fecal pellets that were obtained directly from mice every 3 days. Serial dilutions were made in PBS and plated on MacConkey plates. Counted bacterial colonies are represented as CFU per g feces. (D) H&E staining of representative longitudinal sections of the medial colon of *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice, 18 days after infection. (E) Histological score of proximal, medial and distal colon longitudinal sections, 18 days after infection. An independent pathologist performed scoring blind. Maximal scores were 13, judged by mononuclear cell infiltration (3), epithelial integrity (4), hyperplasia (4) and edema (2). (F) *C. rodentium* counts of spleen homogenates. Serial dilutions were made in PBS and plated on MacConkey plates. Counted bacterial colonies are represented as CFU per g spleen tissue.

the immune activation in the colonic lamina propria was assessed. The colonic lamina propria of *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice showed an influx of phagocytes in the early progressive stage of a *C. rodentium* infection. As predicted from our histopathology analysis (Fig. 4D and E), smaller numbers of CD11b⁺ CD103⁻ macrophages and Ly6G⁺ neutrophils were detected in the lamina propria of *Slamf6*^{-/-} *Rag*^{-/-} mice compared with *Rag*^{-/-} mice 6 days post-infection (Fig. 5A and B).

As judged by quantitative PCR of colon homogenates, a reduced production of the inflammatory cytokine IL-12(p70) was observed in the colons of *Slamf6*^{-/-} *Rag*^{-/-} mice (Fig. 5C). This indicates that fewer inflammatory phagocytes migrate into the lamina propria of *Slamf6*^{-/-} *Rag*^{-/-} mice. These inflammatory cells contribute to the clearance of the infection but can also drive mucosal damage. Without an effective adaptive response, these inflammatory infiltrates contribute to local immune pathology. Therefore,

the reduced pathology in *Slamf6*^{-/-} *Rag*^{-/-} mice could perhaps be explained by impaired monocyte and neutrophil recruitment.

The presence of Slamf6 reduces the production of IL-22 in the colon of infected Slamf6^{-/-} *Rag*^{-/-} mice

IL-22 and the cells that produce it are a key component of protective immunity to *C. rodentium* in the early stages of infection (16, 17). IL-22 production was assessed in infected colons of *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice at days 0, 3 and 6 after infection. As judged by quantitative PCR of mRNA that was isolated from whole colon homogenates and by cytokine analysis of colon culture supernatant, the peak of IL-22 production in both *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice is at day 3 post-infection. At this time, higher amounts of IL-22 were detected in the colon of *Slamf6*^{-/-} *Rag*^{-/-} mice. This




Fig. 5. Reduced lamina propria inflammation during *C. rodentium*-induced colitis of *Slamf6*^{-/-} *Rag*^{-/-} mice. *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice were infected by oral gavage of 2×10^9 *C. rodentium* bacteria. Uninfected *Rag*^{-/-} mice are represented as controls. Animals were sacrificed on day 6 post-infection for analysis. (A) Quantification of flow cytometric analysis of isolated lamina propria macrophages. The total number of CD11c^{hi} MHC-II^{hi} CD11b⁺ CD103⁻ Ly6G⁻ CD45⁺ cells and the percentage of CD11c^{hi} MHC-II^{hi} CD11b⁺ CD103⁻ cells relative to the total pool of Ly6G⁻ CD45⁺ lamina propria cells are represented. (B) Quantification of flow cytometric analysis of isolated lamina propria neutrophils. The total number of CD11b⁺ Ly6G⁺ CD45⁺ cells and the percentage of CD11b⁺ Ly6G⁺ relative to the total pool of CD45⁺ lamina propria cells are represented. (C) Quantitative PCR relative expression of IL-12(p70) in colon homogenates of uninfected *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice and 6 days after infection with *C. rodentium*.

difference reduced to a non-significant level at day 6 post-infection, when IL-22 levels had dropped to 3-fold higher than those of uninfected mice (Fig. 6A and B). As IL-22 is one of the key protective cytokines during *C. rodentium* infections, this observation may contribute to the reduced pathology and lower number of translocated bacteria in *Slamf6*^{-/-} *Rag*^{-/-} mice (Fig. 4F). As IL-22 production is driven primarily by IL-23, colon cultures were assessed for the production of this cytokine after *C. rodentium* infection. In contrast to the IL-12(p70) subunit of the IL-12 cytokine, *Slamf6*^{-/-} *Rag*^{-/-} colons produced more IL-12/IL-23(p40) (Fig. 6C), suggesting an enhanced production of IL-23 in *Slamf6*^{-/-} *Rag*^{-/-} mice. Interestingly, Slamf6 expression was detected in a small set of CD45.2⁺ CD90.2⁺ CD127⁺ ROR γ t⁺ (ILC3) cells, which represent the main producers of IL-22 in *Rag*^{-/-} mice (Supplementary Figure 1C, available at *International Immunology Online*) (14, 17).

Administering a mAb directed against Slamf6 reduces *C. rodentium* colitis in *Rag*^{-/-} mice

In order to test whether the anti-Slamf6 mAb, which inhibits the cognate interactions of Slamf6 with bacteria in the recognition assay (Fig. 1), affects the bacterial colitis pathology, *Rag*^{-/-} mice were intra-peritoneally injected with anti-Slamf6 or isotype (100 μ g) 1 day before and every 7 days after *C. rodentium* infection (Fig. 7A). *Rag*^{-/-} mice that received the anti-Slamf6 mAb showed a delay in their weight loss, a reduction of fecal *C. rodentium* burden at the peak of infection and an increased survival rate (Fig. 7B–D). These findings suggest that blocking the interaction of Slamf6 with bacteria reduces the pathology of *C. rodentium*-induced colitis.

Discussion

In this report, we provide evidence that *Slamf6*^{-/-} *Rag*^{-/-} mice are markedly less susceptible to *C. rodentium*-induced colitis

than *Rag*^{-/-} mice. Through the course of infection, *Slamf6*^{-/-} *Rag*^{-/-} mice show a reduction in the inflammatory response in the lamina propria of the colon. Fewer bacteria translocate to the spleen of *Slamf6*^{-/-} *Rag*^{-/-} mice and ultimately the infection is fatal in a significantly lower percentage of infected mice when compared with co-housed control *Rag*^{-/-} mice. Moreover, anti-Slamf6 mAb treatment of infected *Rag*^{-/-} mice improves the disease outcome associated with less weight

loss, an improved survival rate and a reduction in the fecal *C. rodentium* burden.

Our *in vitro* observation that Slamf6 can interact with certain Gram⁻ bacteria suggests that the reduced colitis displayed by *Slamf6*^{-/-} *Rag*^{-/-} mice in the context of *C. rodentium* infections might be mediated by the absence of the binding of Slamf6 to this bacterium. The observations that anti-Slamf6 mAb inhibited bacterial binding and that *in vivo* administration of this antibody reduced the pathology of infected *Rag*^{-/-} mice further corroborate this notion.

The balance between immune activation and mucosal protection is one of the defining factors in the pathogenic outcome of a *C. rodentium* infection. Whereas a range of key regulators of innate immune responses is indispensable for an effective response to *C. rodentium*, not all innate mechanisms are beneficial to the host. Several recent review articles discuss how innate receptors are involved in detection of *C. rodentium* (21, 26–28). Two major receptor families mediate inflammatory signaling in response to *C. rodentium*: Toll-like receptors and Nod-like receptors, both of which utilize the NF- κ B pathway. Interestingly, TLR4 signaling does not appreciably contribute to host protection against *C. rodentium* but rather enhances mucosal pathologic immune responses (29). Contrary to this, TLR2 signaling promotes inflammatory responses as well as mucosal integrity (30, 31). The authors of these studies argue that TLR4-mediated immune activation drives immune pathology during *C. rodentium* infections, which can be reduced by the protective function of TLR2 (27). Along similar lines, an excess of IL-1 β is detrimental to infected mice, whereas normal levels are required for an




Fig. 6. Enhanced IL-22 production in *Slamf6*^{-/-} *Rag*^{-/-} mice during *C. rodentium*-induced colitis. *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice were infected by oral gavage of 2×10^9 *C. rodentium* bacteria. Uninfected *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice are represented as controls (day 0). Animals were sacrificed on day 3 or day 6 post-infection for analysis. (A) Quantitative PCR relative expression of IL-22 in colon homogenates. (B) IL-22 production of *ex vivo*-cultured colon tissue. (C) *Ex vivo* IL-23(p40) production by 3-day-infected colon tissue cultures.




Fig. 7. Administering a mAb directed against Slamf6 ameliorates *C. rodentium*-induced colitis in *Rag*^{-/-} mice. (A) Infection and treatment diagram for *Rag*^{-/-} mice that were intra-peritoneally injected with 100 μ g anti-Slamf6 mAb (330) 1 day prior to infection and subsequently every seventh day after the first injection. Control mice were injected with 100 μ g mouse IgG2a in the same regimen. (B) The weight of individual mice was measured every 4 days and represented as a percentage of their weight on the day of infection. (C) Survival of infected anti-Slamf6 mAb-treated and isotype-treated *Rag*^{-/-} mice. (D) *C. rodentium* counts in fecal pellets that were obtained directly from mice every 3 days. Serial dilutions were made in PBS and plated on MacConkey plates. Counted bacterial colonies are represented as CFU per g feces.

appropriate response to *C. rodentium* (32). From our data in *Rag*^{-/-} mice, we conclude that *Slamf6* also breaks tolerance and enhances inflammatory responses.

An interesting notion is that *Slamf6* appears to affect the development of colitis only in *Rag*^{-/-} mice. T cells and B cells play key roles in the development of an adequate immune response to *C. rodentium*. Mice that are impaired in their ability to mount a specific humoral response to the bacterium are unable to generate sterilizing immunity (11). However, the protective role of CD4⁺ T cells appears to be 2-fold: the direct protective effects of lesion-proximal T cells and eventually T-cell help to induce a sterilizing humoral immune response. μ MT mice, which lack B cells, but have T cells, develop a milder colitis than *Rag*^{-/-} mice (12). Additionally, *Rag*^{-/-} mice in which CD4⁺ T cells were adoptively transferred show more inflammation, but also better mucosal protection (22). Both T_h1 and T_h17 cells have been implicated in the immune response to *C. rodentium* (21). The lesions at sites of *C. rodentium* infections are associated with IFN γ -producing T_h1 clusters that contribute to the local response to the infection (10, 24). T_h17 development contributes to a protective response and CD4⁺ T-cell depletion leads to an exacerbated pathology and increased loss of barrier function. Although *Slamf6* negatively affects IL-17A production by CD4⁺ T cells, this suppressed T_h17 response does not appear to significantly affect the pathology that is caused by *C. rodentium* infections. The observations that *Slamf6* contributes to the pathology in *Rag*^{-/-} mice, but not WT mice, are likely due to the lack of CD4⁺ T cells that play a protective role in mucosal integrity as differences in immune activation between *Rag*^{-/-} and *Slamf6*^{-/-} *Rag*^{-/-} mice precede the time when a humoral response would arise in WT mice.

Ample studies have addressed functions of Slam receptors in lymphocyte and phagocyte functions. However, little is known about their functions in mucosal phagocytes and innate lymphocytes. Here, we show that *Slamf6* affects the cytokine production of these cells. Interactions of CD103⁻ CX₃CR1⁺ colonic macrophages with *C. rodentium* result in the phagocytosis of the bacterium (14, 15, 33). CX₃CR1-deficient macrophages are impaired in their ability to probe the lumen of the intestine, which in WT as well as *Rag*^{-/-} mice results in decreased IL-22 production and hence increased pathology of *C. rodentium* infection. Thus, interactions of colonic phagocytes with *C. rodentium* result in the production of IL-22 by phagocyte-proximal innate lymphocytes in *Rag*^{-/-} mice (33). In another study, the role of IL-22 in the innate immunity to *C. rodentium* infection was clearly demonstrated utilizing an IL-22-specific antibody. Administration of this antibody to *Rag*^{-/-} mice led to rapid weight loss, more severe colitis and expedited mortality (17). Conversely, vitamin D receptor-deficient mice have higher numbers of ILC3 and produce more IL-22. Consequently, these mice have a reduced bacterial burden and lower immune activation (34).

In this study, we report that *Slamf6* interacts with several Gram⁻ bacterial, including *C. rodentium*. Furthermore, *Slamf6*^{-/-} *Rag*^{-/-} mice produce significantly higher amounts of IL-22 during *C. rodentium* infections. Higher levels of IL-22 result in stronger mucosal protection, thereby lessening epithelial damage (21). We therefore speculate that engagement of *C. rodentium* by *Slamf6* negatively

affects phagocyte-induced signals that promote IL-22 production. Longman *et al.* (14) have shown that IL-23 and IL-1 β production by phagocytes plays a role in the induction of IL-22 production by ILC3 cells. We report that infected colons of *Slamf6*^{-/-} *Rag*^{-/-} mice produce less IL-12(p70) and more IL-12/23(p40). Thus, *Slamf6* has important implications in the development of a colonic innate immune response to pathogenic Gram⁻ bacterial challenge. *Slamf6*-deficiency in innate cells renders the outcome of *C. rodentium*-mediated immune activation more inflammatory and less protective, which profoundly affects the pathology and survival of *Slamf6*^{-/-} *Rag*^{-/-} mice.

Supplementary data

Supplementary data are available at *International Immunology* Online.

Funding

National Institutes of Health (RO1 NIH AI-15066 to C.T.).

Acknowledgements

We thank members of the Terhorst lab and Balthasar Heesters for thoughtful discussions.

Conflict of interest statement: The authors declared no conflict of interest.

References

- Calpe, S., Wang, N., Romero, X. *et al.* 2008. The SLAM and SAP gene families control innate and adaptive immune responses. *Adv. Immunol.* 97:177.
- Kageyama, R., Cannons, J. L., Zhao, F. *et al.* 2012. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. *Immunity* 36:986.
- Qi, H., Cannons, J. L., Klauschen, F., Schwartzberg, P. L. and Germain, R. N. 2008. SAP-controlled T-B cell interactions underlie germinal centre formation. *Nature* 455:764.
- Tatsuo, H., Ono, N., Tanaka, K. and Yanagi, Y. 2000. SLAM (CDw150) is a cellular receptor for measles virus. *Nature* 406:893.
- Malaviya, R., Gao, Z., Thankavel, K., van der Merwe, P. A. and Abraham, S. N. 1999. The mast cell tumor necrosis factor alpha response to FimH-expressing *Escherichia coli* is mediated by the glycosylphosphatidylinositol-anchored molecule CD48. *Proc. Natl Acad. Sci. USA* 96:8110.
- Berger, S. B., Romero, X., Ma, C. *et al.* 2010. SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages. *Nat. Immunol.* 11:920.
- Ma, C., Wang, N., Detre, C., Wang, G., O'Keeffe, M. and Terhorst, C. 2012. Receptor signaling lymphocyte-activation molecule family 1 (*Slamf1*) regulates membrane fusion and NADPH oxidase 2 (NOX2) activity by recruiting a Beclin-1/Vps34/ultraviolet radiation resistance-associated gene (UVRAG) complex. *J. Biol. Chem.* 287:18359.
- Engel, P., Eck, M. J. and Terhorst, C. 2003. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. *Nat. Rev. Immunol.* 3:813.
- Guttman, J. A., Li, Y., Wickham, M. E., Deng, W., Vogl, A. W. and Finlay, B. B. 2006. Attaching and effacing pathogen-induced tight junction disruption *in vivo*. *Cell. Microbiol.* 8:634.
- Chan, J. M., Bhinder, G., Sham, H. P. *et al.* 2013. CD4⁺ T cells drive goblet cell depletion during *Citrobacter rodentium* infection. *Infect. Immun.* 81:4649.
- Vallance, B. A., Deng, W., Knodler, L. A. and Finlay, B. B. 2002. Mice lacking T and B lymphocytes develop transient colitis and

- crypt hyperplasia yet suffer impaired bacterial clearance during *Citrobacter rodentium* infection. *Infect. Immun.* 70:2070.
- 12 Simmons, C. P., Clare, S., Ghaem-Maghami, M. *et al.* 2003. Central role for B lymphocytes and CD4+ T cells in immunity to infection by the attaching and effacing pathogen *Citrobacter rodentium*. *Infect. Immun.* 71:5077.
 - 13 Niess, J. H., Brand, S., Gu, X. *et al.* 2005. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* 307:254.
 - 14 Longman, R. S., Diehl, G. E., Victorio, D. A. *et al.* 2014. CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. *J. Exp. Med.* 211:1571.
 - 15 Schreiber, H. A., Loschko, J., Karssemeijer, R. A. *et al.* 2013. Intestinal monocytes and macrophages are required for T cell polarization in response to *Citrobacter rodentium*. *J. Exp. Med.* 210:2025.
 - 16 Ota, N., Wong, K., Valdez, P. A. *et al.* 2011. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with *Citrobacter rodentium*. *Nat. Immunol.* 12:941.
 - 17 Zheng, Y., Valdez, P. A., Danilenko, D. M. *et al.* 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat. Med.* 14:282.
 - 18 Keszei, M., Detre, C., Rietdijk, S. T. *et al.* 2011. A novel isoform of the Ly108 gene ameliorates murine lupus. *J. Exp. Med.* 208:811.
 - 19 Powrie, F., Leach, M. W., Mauze, S., Caddle, L. B. and Coffman, R. L. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. *Int. Immunol.* 5:1461.
 - 20 Cao, E., Ramagopal, U. A., Fedorov, A. *et al.* 2006. NTB-A receptor crystal structure: insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family. *Immunity* 25:559.
 - 21 Rubino, S. J., Geddes, K. and Girardin, S. E. 2012. Innate IL-17 and IL-22 responses to enteric bacterial pathogens. *Trends Immunol.* 33:112.
 - 22 Bry, L., Brigl, M. and Brenner, M. B. 2006. CD4+-T-cell effector functions and costimulatory requirements essential for surviving mucosal infection with *Citrobacter rodentium*. *Infect. Immun.* 74:673.
 - 23 Uhlig, H. H., McKenzie, B. S., Hue, S. *et al.* 2006. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. *Immunity* 25:309.
 - 24 Shiomi, H., Masuda, A., Nishiumi, S. *et al.* 2010. Gamma interferon produced by antigen-specific CD4+ T cells regulates the mucosal immune responses to *Citrobacter rodentium* infection. *Infect. Immun.* 78:2653.
 - 25 Ishigame, H., Kakuta, S., Nagai, T. *et al.* 2009. Differential roles of interleukin-17A and -17F in host defense against mucocutaneous bacterial infection and allergic responses. *Immunity* 30:108.
 - 26 Collins, J. W., Keeney, K. M., Crepin, V. F. *et al.* 2014. *Citrobacter rodentium*: infection, inflammation and the microbiota. *Nat. Rev. Microbiol.* 12:612.
 - 27 Bergstrom, K. S., Sham, H. P., Zarepour, M. and Vallance, B. A. 2012. Innate host responses to enteric bacterial pathogens: a balancing act between resistance and tolerance. *Cell. Microbiol.* 14:475.
 - 28 Liu, Z., Zaki, M. H., Vogel, P. *et al.* 2012. Role of inflammasomes in host defense against *Citrobacter rodentium* infection. *J. Biol. Chem.* 287:16955.
 - 29 Khan, M. A., Ma, C., Knodler, L. A. *et al.* 2006. Toll-like receptor 4 contributes to colitis development but not to host defense during *Citrobacter rodentium* infection in mice. *Infect. Immun.* 74:2522.
 - 30 Gibson, D. L., Ma, C., Rosenberger, C. M. *et al.* 2008. Toll-like receptor 2 plays a critical role in maintaining mucosal integrity during *Citrobacter rodentium*-induced colitis. *Cell. Microbiol.* 10:388.
 - 31 Gibson, D. L., Montero, M., Ropeleski, M. J. *et al.* 2010. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. *Gastroenterology* 139:1277.
 - 32 Alipour, M., Lou, Y., Zimmerman, D. *et al.* 2013. A balanced IL-1 β activity is required for host response to *Citrobacter rodentium* infection. *PLoS One* 8:e80656.
 - 33 Manta, C., Heupel, E., Radulovic, K. *et al.* 2013. CX(3)CR1(+) macrophages support IL-22 production by innate lymphoid cells during infection with *Citrobacter rodentium*. *Mucosal Immunol.* 6:177.
 - 34 Chen, J., Waddell, A., Lin, Y. D., and Cantorna, M. T. 2014. Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to *Citrobacter rodentium* through modulation of innate lymphoid cells. *Mucosal Immunol.* 3:618.